Member Info for B2HS2L

That's one less essay reader wyndrum.

Your readership is decrementing daily, - soon you'll be writing to yourself.

Best you bugger off now while the going is good.

Https://www.linkedin.com/in/kim-hart-paulsen-9949386/ Vice President Clinical Operations at Avacta Therapeutics, Riverton, New Jersey, United States

https://www.linkedin.com/in/heather-mcguiness-aa87995/ Associate Director at Avacta Therapeutics, New Haven, Connecticut, United States

https://www.linkedin.com/in/christina-burke-623399188/ Senior Scientist @ Avacta Therapeutics | PhD in Immuno-oncology, London, England, United Kingdom

Thanks for the prompt Gmcc.

"For AVCT holders the read-through is twofold.

First, the balance sheet is being actively de-risked before major data events, removing an overhang that has weighed on the stock for two years.

Second, the cash-versus-shares choice signals board confidence that the current share price is not the level at which they want to be diluting holders.

The unresolved risk is that further quarterly repayments through 2026 and into 2027 will need either continued cash outflow or fresh fundraising, and the timing of that against clinical newsflow will decide how gently the runway extends."

Fine as far as it goes. However, what do prospective partners / licensee's et al think of Avacta's finances?

Surely there have been deals built on worse financial platforms, but at least we can be seen to be paying repayments in cash.

Is this financial outlook for prospective partners a part of the reason Avacta has selected a deputy Chairman with such a pedigree.

May 29, 2026 - Worth reading again now the Deputy Chairman has arrived.

https://business-news-today.com/avacta-therapeutics-aim-avct-names-richard-hughes-chairman-as-shaun-chilton-steps-back/

What does the new deputy chairman appointment signal about Avacta Therapeutics pharma partnering ambitions?

The quieter but arguably more telling line in the announcement is the creation of a deputy chairman role earmarked for someone with global biotechnology expertise. Layering in a deputy with sector depth, on top of a chair drawn from capital markets, looks like a deliberate attempt to balance the boardroom across two competencies that a partnering-stage biotech needs in equal measure: the financial nous to raise and deploy capital, and the scientific and commercial credibility to sit opposite large pharmaceutical counterparties.

This is a board being engineered for negotiation. Avacta Therapeutics has been explicit that it is engaging potential pharmaceutical partners for its pre|CISION oncology candidates, and partnering discussions with global drug majors are won or lost on the quality of the people in the room. A deputy chairman with a recognised biotech track record gives the company a senior figure who can speak the language of partner due diligence and validate the science to a counterparty’s satisfaction. The second-order implication is that management is signalling confidence that its lead assets are far enough along to attract that kind of conversation. Boards do not usually retool for deal-making unless they believe deals are realistically in view.

+++

etc

May 29, 2026

https://business-news-today.com/avacta-therapeutics-aim-avct-names-richard-hughes-chairman-as-shaun-chilton-steps-back/

Worth reading again now the Deputy Chairman has arrived.

Top 5 companies to watch:

1 Bicycle Therapeutics

I posted this on 11 May 2026:

Grok queery: Are Bicycle therapeutics reducing headcount?

Yes, Bicycle Therapeutics (NASDAQ: BCYC) is reducing its headcount by approximately 30%.

The company announced this on March 17, 2026, as part of its Q4 and full-year 2025 financial results and a broader strategic reprioritization.

It plans to cut about 86 positions from its ~288 employees (as of the end of 2025), leaving roughly 200 staff.

This move is intended to halve annual operating expenses and extend its cash runway into 2030.

The reduction follows a prior 25% workforce cut in August 2025, which left around 280 employees at that time.

+++

!

From Grok

Is 'Molecular Analysis for Precision Oncology (MAP) Congress 2026' (10–11 September 2026 in London) a deal making or a technical developments / update meeting?

Primarily a technical developments / scientific and translational update meeting, not a major deal-making or partnering event.

esmo.org

What the MAP Congress Focuses On

The Molecular Analysis for Precision Oncology (MAP) Congress, organized by ESMO in partnership with Cancer Research UK (CRUK) and others, is a specialized scientific meeting dedicated to:

Advances in molecular profiling of tumors.

Translational research bridging basic cancer biology, diagnostics, and personalized/precision oncology treatments.

Topics like molecular mechanisms of cancer (e.g., prevention, metastasis, resistance), new biomarkers, diagnostics innovation, and early clinical translation.

It emphasizes cutting-edge research, abstract presentations, expert discussions, and interdisciplinary exchange among researchers, clinicians, and translational scientists.

Past editions highlight molecular insights, trial data with a strong lab-to-clinic focus, and updates on technologies that could inform future therapies.

Deal-Making vs. Technical Focus

Not primarily deal-making: Unlike large industry-heavy events (e.g., BIO International, JP Morgan, or even the main ESMO Congress), MAP is smaller, more academically and scientifically oriented. It has limited emphasis on high-profile partnering suites, investor matchmaking, or big pharma BD-heavy activities.

For Avacta’s “further analyses” of AVA6000 Phase 1a/1b clinical/translational data (efficacy, safety, PK, etc.), MAP would be a strong technical fit — ideal for presenting detailed molecular or precision-oncology-related findings. It’s more academic/scientific than a pure business development venue.

+++

However - no reason why Avacta can't meet and greet interested BP at this time.

That's Pat Vink PLUS Yulii Bogatyrenko right?

Horses for Courses.

Your so VICTIMISED on here wyndrum.

It's a wonder you don't find another board to infest.

Spend some of that trading profit of yours on getting your head fixed.

Bogatyrenko announced thus 01.07.2025:

'Mr. Bogatyrenko is a Principal at Biopharma C&I, a biotechnology consulting firm that works with private and public companies in business development, corporate strategy, commercialization, launch readiness and R&D strategy. Previously, he held senior level positions in business development and commercial strategy, including leading multiple global commercial drug launches and numerous industry partnerships at Pfizer/Wyeth, Bayer Healthcare and Teva Specialty Pharmaceuticals.'

++++

It seems he could do with some 'finest kind' assistance.

Appearing sporadically in the footer of some recent RNS's:

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Gen Two innovative pre|CISION® sustained release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure.

AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS).

Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload.

+++

This statement will tend to concentrate minds on the 6103 horizon, rather than the ongoing 6000 activity, (including the analysis of the FAPI-PET sub-study) due an update in Q3.

Whilst you on the other hand.

- COLDWATER is ready at wyndrum's beck and call to support his PoV.

Way too obvious wyndrum, You'll still have to buck-up to be useless.

Try another supporting handle - TWAT, though you've probably registered it already.

'But if Novartis is paying good money for a delivery system that isn’t even in clinical trials yet, then why won’t they pay good money for AVA6000'

Avacta is still developing the product, and now knows (as BP now knows) how it will be brought to market thanks to a recent FDA agreement.

More news Q3.

RNS 25.06.2026

'This would comprise a single pivotal study with faridoxorubicin in patients with salivary gland cancer (SGC), with progression-free survival (PFS) as the sole primary endpoint for full approval.

Furthermore, the proposed study population includes both first- and second-line patients, in the most prevalent subsets of SGC, while more rare subsets (e.g. undifferentiated histology and mucinous tumor types) are excluded due to differing natural histories.'

+++

I assume an amount of time must pass before potential partners due diligence is complete.

Avacta won't be ready to select a partner, unless processes are complete, and then we'll be notified.

So probably not soon.

More patience required Touk, - unfortunately for you.

Toukankahmoon

🥱 farcicalist - (privileged to be at the birth of a new word) etc etc.

If every positive dataset strengthens Avacta’s negotiating position, why would management rush into a deal simply to satisfy BP now,

instead of making a deal for a larger sum when Avacta's project(s) are more mature.

Three recent RNS headings:

Platform-Validating Data with Faridoxorubicin 25.06.2026

FDA Agreement on Pivotal Trial Design for AVA6000 25.06.2026

CLINICAL data on AVA6000 in salivary cancers 01.06.2026

Myricx

"the Company is building out its proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform as well as advancing its pipeline of NMTi-ADCs through clinical proof of concept, targeting clinically validated tumour-associated antigens.

Myricx was spun out of Imperial College London and the Francis Crick Institute in 2019."

ADC's were 100% the future in 2019, (seven years ago).

But as time passes and the tech reaches the clinic, the ADC platform will likely be seen to hinder rather than help Myricx, in comparison to PDC tech.

From Grok:

Provide an overview of Myricx Bio trials, products and progress

Myricx Bio (now being acquired by Novartis) is a UK-based biotechnology company (spinout from Imperial College London and the Francis Crick Institute) focused on developing a novel class of antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitors (NMTi) as payloads.

NMT is an enzyme that adds a lipid modification to proteins critical for cancer cell survival. Myricx’s NMTi payloads represent a differentiated, orthogonal mechanism of action compared to dominant ADC payload classes (e.g., tubulin binders, topoisomerase I inhibitors, or DNA binders). Preclinical data have shown strong efficacy, including complete and durable tumor regressions in solid tumor models (including those refractory to TOPO1i ADCs), potent bystander activity, activity across a range of antigen expression levels, and a favorable tolerability profile.

Pipeline and ProductsMyricx has advanced a proprietary pipeline of NMTi-ADCs targeting clinically validated tumor-associated antigens in solid tumors. As of mid-2026, the company was prioritizing two lead proprietary programs:

B7-H3-targeted NMTi-ADC

HER2-targeted NMTi-ADC

These have potential across multiple solid tumor types (e.g., breast, lung, prostate, gastric, and others). The platform has also been evaluated with other targets (e.g., TROP2) in preclinical work.

The company has demonstrated compelling preclinical efficacy and safety, with NMTi-ADCs achieving complete tumor regressions at well-tolerated doses in xenograft and patient-derived models, including in cancers poorly responsive to standard payloads.

Clinical Trials and ProgressPreclinical stage until recently: Myricx nominated its lead development candidate and was on track to enter human clinical trials in 2026.

No clinical trials had started as of the latest public updates (pre-acquisition announcement).

The company had built out its R&D capabilities, expanded leadership (including clinical/regulatory experts), and moved into dedicated London facilities following substantial financing.

Key milestones:Founded ~2019; initially focused on NMTi as small molecules before pivoting to ADC payloads.

Partnerships/collaborations (e.g., with Biocytogen and WuXi Biologics for antibody and ADC work).

£90 million (~$114 million) Series A in 2024 (largest for a UK spinout at the time), led by Novo Holdings and Abingworth, with participation from others including Eli Lilly. Funds supported platform building and advancement to clinical proof-of-concept.

Leadership expansions in 2025 (e.g., new CEO Mohit Rawat, clinical operations, regulatory affairs).

Preclinical data presentations (e.g., AACR, World ADC conferences).

This was where I was coming from earlier:

RNS 19.05.2026:

"· In addition, the Company expects to release data in the TNBC cohort in H1 2026. Further development of faridoxorubicin will be undertaken subject to a partner being secured. The Company continues to engage with multiple partners as the data matures." (In all three cohorts)

Would it have been RH or CC who suggested the 'link it to the data on TNBC'. 🤔

Thanks GMCC, I was word searching on TNBC only.

Thanks also to Agenda101.

However data delivery slip evident, and no idea when TNBC data maturity is now deliverable.